<DOC>
	<DOCNO>NCT01426516</DOCNO>
	<brief_summary>One-third individual treat major depressive disorder ( MDD ) experience remission symptom despite least two adequate antidepressant trial . Such treatment-resistant depression ( TRD ) contribute disproportionately tremendous cost MDD , term health care cost , functional impairment , diminish quality life . The promise personalize medicine individual high risk TRD apparent . If individual could recognize early disease course , could triaged intensive target intervention improve likelihood remission . With proliferation treatment option MDD , present individual spend month year treatment receive next-step treatment . At present , clinical biomarker-based tool show assist match patient treatment likely effective . The Genecept Assay offer possibility `` Personalized Medicine '' psychiatry . Clinicians may find additional genetic information lead optimize treatment plan individual patient . Before assay widely apply clinically , necessary demonstrate tool usefully impact treatment outcomes . This study examine potential impact assay term depression severity 3 month , follow-up 6 month . Secondary measure allow estimate potential change clinician behavior improve patient quality life . Further measure also allow refinement assay maximize patient clinician satisfaction , estimate potential saving associate deployment assay real-world clinical setting .</brief_summary>
	<brief_title>Pharmacogenomics Antidepressant Guidance Education 1 ( PAGE-1_AG1 )</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>age 1865 write informed consent diagnosis nonpsychotic major depression determine study clinician/current medical prescriber , mood disorder diagnosis confirm PHQ9 QIDSSR score least 10 ( i.e. , moderate depression ) initial visit failure least 1 prior adequate trial standard antidepressant ( ATRQ criterion i.e. , 6 week adequate dose ) psychotic feature current episode , base upon clinical assessment 4 fail pharmacologic intervention current major depressive episode [ response rate subject likely extremely low would require substantially largerscale study identify treatment effect ] current substance use disorder nicotine base upon clinical assessment require inpatient outpatient detoxification pregnant woman woman child bear potential use medically accept mean contraception ( include oral contraceptive implant , condom , diaphragm , spermicide , intrauterine device , tubal ligation , partner vasectomy ) woman breastfeed serious suicide homicide risk , assess evaluate clinician unstable medical illness include cardiovascular , hepatic , renal , respiratory , endocrine , neurological , hematological disease , base review medical history , physical examination , screen laboratory test patient take investigational psychotropic drug within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Treatment Resistant</keyword>
	<keyword>Depression</keyword>
</DOC>